Risk factor
Low price volatility
Profitability factor
Decent dividends
About
Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan. It offers Dayvigo, for the treatment of insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; Methycobal for the treatment of peripheral...
Company Valuation
Based on key historical and expected multiples, the stock is fairly valued relative to its peers. Specifically, the stock is 'expensive' on P/E, neutral on EV/EBITDA, rea
Target Price
The average target price of 4523.T is 5135 and suggests 7% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendation
Buy
Sell